Bob Dibble (@BobDibble8) profile picture
Joined January 2018
#avct the science is now compelled but the sp needs commercial validation If the clinical evidence is now sufficiently compelling to support a major pharmaceutical partnership, what specifically is preventing that partnership from being concluded?
2
1
12
2,195
#avct What I want by year end : AVA6K partnership, with upfront payment. OR Evidence that negotiations have reached an advanced commercial stage. + An explanation of the expected timing/structure of a partnership. + A funding strategy that minimises a discounted equity raise.
1
20
1,269
AVCT good ESMO data and note STS and TNBC data still maturing, will this land before year end? Unusually no mention of discussions with partners, maybe talks now more advanced?
1
2
400
I expect the ESMO SGC data to be excellent. This should secure a deal. How much would be the going rate for a £250+m annual income for pharma? Ignoring other 6K indications.
4
182
#avct. RAH can’t reply to your post 2hrs ago as you’ve blocked me for years BUT if you ask ChatGPT the answer is quite interesting.
1
1
4
3,630
#avct AVA6000 is not just SGC can we please have an update on STS and TNBC. Data should be mature enough to determine whether patients are responding, at least it would show 6K is not a one indication drug.
1
16
2,267
#avct I’m a true believer in the science but if there’s no post ESMO deal then I think it’s fair to ask “ Have Avacta’s discussions progressed to due diligence, proposals or commercial negotiations — and, if they haven’t, why not after the AVA6103 proof-of-mechanism data?”
1
1
23
3,120
#avct time for a genuine Business Update with a commercial twist imo. You cannot continually state you are in discussions with several potential partners then do a bog standard raise and repeat the same statement. Shldrs deserve more.
6
1
56
3,437
I’m looking at this asa very positive development. If institutions come on board at or even above the current sp with a raise that allows Heights repayment and runway extension then the market can value on the science. ESMO reveal very interesting.
1
166
#avct this from ChatGPT makes sense: Avacta appears to be deliberately taking the share price out of the equation temporarily so it can negotiate/discover the valuation at which investors are prepared to fund the company.
1
21
2,798
Brilliant award win for Avacta just a waiting game now till ESMO. I’m confident the wait will be worth it though.
2
9
385
#avct 6103 data looking more and more significant for a rerate if excellent. We’ll see if there’s any leaks by sp action ahead of the conference.
1
11
1,219
#avct the Zeus note starts at 109 p and assumes good 6103 data readout in Q3. Ask ChatGPT ‘what does the Zeus broker note imply for Avacta?’ Interesting read!
8
1,276
#avct for me this is really good news. The management team deserve the awards and Avacta has secured their employment to carry the company forward. Now let’s have news for shareholders.
39
1,446
#avct I still think talk of a TO is a bit early. With the sum needed to be successful BP will have to be very sure of the data. 6103 data if excellent will move discussions but unless there’s a first mover situation I think they’ll wait for more data. So deal first imo.
3
1
22
4,649
#avct news rich period to year end: 6K TNBC data 6K STS data Licence deal for SGC or above or whole of 6K, either regional or global 6103 initial data ESMO presentation. Should be an interesting time for us shldrs.
4
3
54
4,810
#avct AVA6000 (Faridoxorubicin) should not be overlooked by the H2 data for 6103. The current global market spend for TNBC, SGC and STS is appx $4.5 bn. annually. It’s inconceivable BP would not be interested if data trends and FDA confidence persists.
2
33
4,980
#avct AZ have to be all over every step of the 6103 data given the comparisons to enhertu. For them it’s a direct target and one they will want to respond to eventually.
1
2
48
4,392
#avct in talks with many prospective partners: AVA6000 SGC AVA6000 STS AVA6000 TNBC AVA6000 Gen1 as a whole AVA6103 exatecan tamer, data due soon. A deal for any either regional or global could land at any time. So many prospects, rerate must occur.
1
3
39
2,692
#avct AI comment, usual caveats,: likely topics are: * safety and tolerability, * (PK), * (PD), * biomarker findings, * evidence that pre|CISION is releasing exatecan selectively in tumours, * perhaps early signs of anti-tumour activity if any observed.
1
7
1,258